Navigation Links
EpiCept Corporation Announces Pricing of Public Offering
Date:12/4/2007

opment of our other apoptosis product candidates will not be successful, the risk that our ASAP technology will not yield any successful product candidates, the risk that clinical trials for NP-1 or EPC 2407 will not be successful, that NP-1 or EPC 2407 will not receive regulatory approval or achieve significant commercial success, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with dependence upon key personnel, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with prior material weaknesses in our internal controls; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov or at http://www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN

* Azixa is a registered trademark of Myriad Genetics, Inc.


'/>"/>
SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. EpiCept Corporation to Present at the 2007 BIO InvestorForum
2. EpiCept to Present Preclinical Studies of EPC2407 in Combination With Anti-Angiogenic and Chemotherpeutic Agents at the AACR-NCI-EORTC International Conference
3. EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. EpiCept To Host Third Quarter 2007 Conference Call and Webcast on November 7, 2007
5. EpiCept Corporation Reports Third Quarter 2007 Operating and Financial Results
6. EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference
7. Patient Enrollment Completed in Phase IIb Trial of EpiCept(TM) NP-1 in Diabetic Peripheral Neuropathy
8. EpiCept Announces Presentation of New Ceplene(TM) Data at the 49th Annual Meeting of the American Society of Hematology
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 26, 2014 Yisrayl Hawkins, Pastor at The ... letter in light of the Ferguson, Missouri unrest. Yisrayl starts ... unrest and explains why it has only increased. , ... even created. He says there is a very specific reason ... says there is a set of rules, or Laws that ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... The Damon Runyon Cancer Research Foundation named ... April 2010 Clinical Investigator Award Committee review. ... outstanding early career physician-scientists conducting patient-oriented cancer research ... the nation,s leading scientists and clinicians. Each will ...
... new magnetic resonance imaging technology that could revolutionise the ... take a major step forward as a 7m research ... Hyperpolarisation with parahydrogen is a technique developed at the ... resonance imaging (MRI), the scanning technology widely used in ...
... ... release of their new Alpha 3C™ formula, designed to naturally support focus, calmness ... ... of premium dietary supplements, announces the release of their new Alpha 3C™ formula, ...
... therapy made from a human protein significantly decreases disease ... a new asthma therapy for patients who do not ... in an animal model were presented at The Endocrine ... protein, insulin-like growth factor binding protein-3 (IGFBP-3), uniquely inhibits ...
... ... order to attract patients, compete effectively, grow their revenues, counter the declining economy and ... ... doctor and physician marketing firm Heathcare Success Strategies , doctors are increasingly resorting ...
... ... achieve greater athletic outcomes and increase their performance. , ... Pittsburgh, PA (PRWEB) June 28, ... premiere health care facilities, is an organization of physicians and health care professionals ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 3Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 4Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 5Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 6Health News:New scanning technology developed in £7M research center 2Health News:Purity Products Releases Alpha 3C 2Health News:Experimental nonsteroidal treatment of asthma shows promise 2Health News:Doctors and Medical Groups Increasingly Embrace Physician Marketing to Counter Changes in Health Care 2Health News:Allegheny Medical's SportsCare Programs Combine Lifestyle, Fitness and Behavior Management with Quality Medical Treatments 2
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... YORK and LONDON , ... global orthopedic industry are expected to grow at an ... in terms of value and volume. Hip, knee and ... developed world while in emerging economies they have a ... rates are challenging the use of composites. Non-metallic orthopedic ...
Breaking Medicine Technology:Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 25 LigoCyte Pharmaceuticals, Inc. , a ... today announced positive results from a Phase I/II ... vaccine candidate. Baylor College of Medicine,s Robert Atmar, ... the trial via an oral presentation at the ...
... Oct. 25 Express Scripts, Inc. (Nasdaq: ... following investor conferences in November:Oppenheimer 21st Annual Healthcare Conference ... Suisse 2010 Healthcare Conference on Wednesday, November 10, 2010 ... 7th Annual Healthcare Conference on Tuesday, November 16, 2010 ...
Cached Medicine Technology:Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 2Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 3Positive Results From LigoCyte's Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting 4Express Scripts to Present at Investor Conferences in November 2
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
... CKX microscopes utilize the infinity-corrected ... and operability in cell checking. ... inverted microscope suited to routine ... fields--from tissue culture and embryology ...
... was designed from the ground-up with ergonomic ... height and most adjustable observation tube on ... that every user can adjust the microscope ... flexibility helps the operator maintain an upright, ...
Medicine Products: